Effects of telmisartan with hydrochlorothiazide versus valsartan with hydrochlorothiazide in patients with moderate-to-severe hypertension

International Journal of Hypertension

Volumn 2012, Issue , 2012, Pages

  Marfatia, Ravi ^a   White, William B ^a   Schumacher, Helmut ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MODERATE TO SEVERE HYPERTENSION; MULTICENTER STUDY; MUSCLE SPASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA;

EID: 84867637963     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2012/976828     Document Type: Article

References (26)

1. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. Journal of the American Medical Association 2003 289 19 2560 2572 2-s2.0-0038460302 10.1001/jama.289.19.2560 (Pubitemid 37430158)
2. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A. M., Kjeldsen S. E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R. E., Boudier H. A. J. S., Zanchetti A., 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007 25 6 1105 1187 2-s2.0-34250350040 10.1097/HJH.0b013e3281fc975a (Pubitemid 46924065)
3. McGill J. B., Reilly P. A., Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clinical Therapeutics 2001 23 6 833 850 2-s2.0-0034984319 10.1016/S0149-2918(01)80072-2 (Pubitemid 32554566)
4. Ruddy M. C., Oparil S., Weber M. A., Angiotensin II receptor antagonists. Hypertension: A Companion to Brenner and Rector's The Kidney 2000 Philadelphia, Pa, USA WB Saunders Company 621 637
5. Dahlöf B., Sever P. S., Poulter N. R., Wedel H., Beevers D. G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Östergren J., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 2005 366 9489 895 906 2-s2.0-24644443331 10.1016/S0140-6736(05)67185-1 (Pubitemid 41265663)
6. Jamerson K., Weber M. A., Bakris G. L., Dahlöf B., Pitt B., Shi V., Hester A., Gupte J., Gatlin M., Velazquez E. J., Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England Journal of Medicine 2008 359 23 2417 2428 2-s2.0-57349138291 10.1056/NEJMoa0806182
7. Cice G., Di Benedetto A., D'Isa S., D'Andrea A., Marcelli D., Gatti E., Calabr R., Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial. Journal of the American College of Cardiology 2010 56 21 1701 1708 2-s2.0-78349252300 10.1016/j.jacc.2010.03.105
8. Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., De Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L. H., Nieminen M. S., Omvik P., Oparil S., Wedel H., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 2002 359 9311 995 1003 2-s2.0-0037160968 10.1016/S0140-6736(02)08089-3 (Pubitemid 34286536)
9. Julius S., Kjeldsen S. E., Weber M., Brunner H. R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G. T., Mitchell L., Plat F., Schork A., Smith B., Zanchetti A., Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 2004 363 9426 2022 2031 2-s2.0-2942635317 10.1016/S0140- 6736(04)16451-9 (Pubitemid 38781102)
10. Maggioni A. P., Latini R., Carson P. E., Singh S. N., Barlera S., Glazer R., Masson S., Cerè E., Tognoni G., Cohn J. N., Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal 2005 149 3 548 557 2-s2.0-17844369714 10.1016/j.ahj.2004.09.033 (Pubitemid 40585420)
11. McMurray J., Solomon S., Pieper K., Reed S., Rouleau J., Velazquez E., White H., Howlett J., Swedberg K., Maggioni A., Køber L., Van De Werf F., Califf R., Pfeffer M., The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the valsartan in acute myocardial infarction trial (VALIANT). Journal of the American College of Cardiology 2006 47 4 726 733 2-s2.0-32644482770 10.1016/j.jacc.2005.09.055 (Pubitemid 43245597)
12. Pfeffer M. A., Swedberg K., Granger C. B., Held P., McMurray J. J. V., Michelson E. L., Olofsson B., Östergren J., Yusuf S., Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. The Lancet 2003 362 9386 759 766 2-s2.0-0042410539 10.1016/S0140-6736(03)14282-1 (Pubitemid 37093915)
13. Yusuf S., Teo K. K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., Anderson C., Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine 2008 358 15 1547 1559 2-s2.0-42049107348 10.1056/NEJMoa0801317 (Pubitemid 351522739)
14. Moser M., Update on the management of hypertension: recent clinical trials and the JNC 7. Journal of Clinical Hypertension 2004 6 10, supplement 2 4 13 2-s2.0-12344317534
15. White W. B., Punzi H. A., Murwin D., Koval S. E., Davidai G., Neutel J. M., Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. Journal of Clinical Hypertension 2006 8 9 626 633 2-s2.0-34547100641
16. White W. B., Murwin D., Chrysant S. G., Koval S. E., Davidai G., Guthrie R., Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Pressure Monitoring 2008 13 1 21 27 2-s2.0-38349042145 10.1097/MBP. 0b013e3282f3859d
17. White W. B., Davidai G., Schumacher H., Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. Journal of Human Hypertension 2009 23 12 817 825 2-s2.0-70749086889 10.1038/jhh.2009.28
18. Benz J. R., Black H. R., Graff A., Reed A., Fitzsimmons S., Shi Y., Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. Journal of Human Hypertension 1998 12 12 861 866 2-s2.0-0032436072 (Pubitemid 29010276)
19. Trenkwalder P., Ulmer H. J., Weidinger G., Handrock R., Efficacy and safety of valsartan 160mg/hydrochlorothiazide 25mg combination in patients with hypertension not adequately controlled by valsartan 160mg/hydrochlorothiazide 12.5mg. Clinical Drug Investigation 2004 24 10 593 602 2-s2.0-21344471995 10.2165/00044011-200424100-00005 (Pubitemid 44283967)
20. Lacourcière Y., Krzesinski J. M., White W. B., Davidai G., Schumacher H., Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Pressure Monitoring 2004 9 4 203 210 2-s2.0-4344665959 10.1097/00126097-200408000-00005 (Pubitemid 39159163)
21. White W. B., Lacourciere Y., Davidai G., Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. American Journal of Hypertension 2004 17 4 347 353 2-s2.0-1842562367 10.1016/j.amjhyper.2004.02.016 (Pubitemid 38446850)
22. Burnier M., Telmisartan: a different angiotensin II receptor blocker protecting a different population? The Journal of International Medical Research 2009 37 6 1662 1679 2-s2.0-74949135696
23. Costa F. V., Telmisartan: standing out in a crowded contest? High Blood Pressure and Cardiovascular Prevention 2006 13 3 85 94 2-s2.0-33749400920 10.2165/00151642-200613030-00003 (Pubitemid 44500566)
24. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 2002 360 9349 1903 1913 2-s2.0-0037079309 10.1016/S0140-6736(02)11911-8 (Pubitemid 35472129)
25. Cook N. R., Cohen J., Hebert P. R., Taylor J. O., Hennekens C. H., Implications of small reductions in diastolic blood pressure for primary prevention. Archives of Internal Medicine 1995 155 7 701 709 2-s2.0-0028927046
26. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 2002 288 23 2981 2997